Further analysis of the peripheral blood mononuclear cells in patients undergoing anti-CTLA-4 treatment for stage IV MM and RCC has highlighted (by means of in vitro co-culture proliferation assay and FOXP3 expression) that there is no inhibition of the suppressive activity of CD4+CD25+ T cells, but a probable enhancement of effector cell function (Maker et al, 2005a) (see Table 2). The gene discussed is FOXP3; the disease is Miyoshi myopathy.